GC Cell participates in JPM Healthcare Conference... "Seeking Global Opportunities for Immuncell-LC Injection"

GC Cell announced on the 20th that it will participate in the 'JP Morgan Healthcare Conference (JPMHC)' held in San Francisco, California, USA, from January 8 to 11 next year.

GC Cell logo [Photo by GC Cell]

JPMHC is the world's largest healthcare investment event where CEOs of about 1,500 pharmaceutical and biotech companies from over 50 countries gather annually to announce their mid- to long-term business plans.

Through participation in this event, GC Cell plans to publicize its mid- to long-term business strategy 'Blueprint 2.0' and understand global market trends to diversify its allogeneic natural killer (NK) and chimeric antigen receptor (CAR)-NK cell therapy pipelines. In addition, GC Cell will participate in 'Bio Partnering @ JPM,' a business partnering meeting held separately from JPMHC, to actively promote technology exchange and business cooperation with global pharmaceutical and biotech companies.

James Park, CEO of GC Cell, stated, “Through participation in this JPMHC, we plan to seek opportunities for clinical collaboration to establish global partnerships for GC Cell’s immunotherapy product ‘ImmunCell-LC Injection’ and to enter the U.S. market.”

ImmunCell-LC Injection is composed mainly of autologous blood-derived T lymphocytes, which are isolated from the patient’s blood and cultured for 2 to 3 weeks to acquire killer cell function. In a phase 3 clinical trial targeting early hepatocellular carcinoma patients, it demonstrated a 37% reduction in recurrence risk and a 79% reduction in mortality compared to the control group. It was subsequently approved as a post-surgical treatment for liver cancer and recently accumulated data from 10,000 treated patients.

This content was produced with the assistance of AI translation services.